In particular, it has been shown that both dendritic- and tumour cell-derived EVs stimulate tumour antigen-specific CD8+ cytotoxic T lymphocyte responses, mediating anti-tumour immunity in experimental animal models and human clinical trials in several types of cancer [146,222] (Figure 5a). This evidence concerns the gene CD8A and neoplasm.